Inpharma 1294 - 30 Jun 2001

■ The human monoclonal antibody ‘HuMax-EGFr’*shows antitumour effects in a murine model,according to data presented at the 18th InternationalConference on Advances in the Application ofMonoclonal Antibodies in Clinical Oncology, heldrecently in Vouliagmeni, Greece. The monoclonalantibody targets the epidermal growth factor receptor(EGFr). Researchers found that administration of‘HuMax-EGFr’ 1 day after introduction of tumour cellsinto mice resulted in complete inhibition of tumourformation at the low total dose of 50µg. When‘HuMax-EGFr’ was given to mice with well-establishedtumours, the monoclonal antibody was capable oftumour eradication at a total dose as low as 125µg.* Genmab; preclinical in colorectal and head and neck cancer

Genmab A/S. Genmab’s HuMax-EGFr eradicates tumors in mouse cancerstudies. Media Release : [2 pages], 13 Jun 2001. Available from: URL: http://www.genmab.com 800861624

1

Inpharma 30 Jun 2001 No. 12941173-8324/10/1294-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved